Assessing the role of ADAM10 in Trastuzumab treatment and resistance

<p>Overexpression of the HER2 receptor occurs in about 15-20% of all breast cancers and is correlated with poor prognosis. Trastuzumab (Herceptin®), a monoclonal antibody targeting HER2, was shown to prolong survival of these patients. However, primary or acquired resistance remains a drawback...

Descrizione completa

Dettagli Bibliografici
Autore principale: Feldinger, K
Altri autori: Kong, A
Natura: Tesi
Lingua:English
Pubblicazione: 2012
Soggetti: